Press release
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025
Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis GAAP operating margin of 21.0% and non-GAAP
About this update from Illumina, Inc.
[{"type":"text","content":"\n Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis\n GAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025\n GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025\n Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025\n Repurchased 1.2 million shares of our common stock for $120 million at an average price of $97.10 per share\n For fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (1.5%) to (0.5%), up from (2.5%) to (1.5%)Revenue growth outside of China in the range of 0.5% - 1.5% on a constant currency basis, with no change versus our prior guidance at the mid-pointNon-GAAP operating margin in the range of 22.75% - 23%, up from 22% - 22.5%Non-GAAP diluted EPS in the range of $4.65 - $4.75, up from $4.45 - $4.55\n \n \n SAN DIEGO, Oct. 30, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (\"Illumina\" or the \"company\") today announced its financial results for the third quarter of fiscal year 2025.\n \"I am pleased to announce that the Illumina team delivered Q325 results that exceeded the high-end of our guidance range for revenue and earnings, driven by revenue acceleration in clinical, our largest market segment,\" said Jacob Thaysen, Chief Executive Officer. \"During the quarter, we returned to growth ex-China and are executing on our strategic pillars that support our long-range financial targets.\"\n \n \n Third quarter results\n \n \n \n \n \n \n \n \n \n \n \n GAAP\n \n \n \n \n \n \n \n \n \n Non-GAAP (a)\n \n \n \n \n \n \n \n \n Dollars in millions, except per share amounts\n \n \n \n \n \n \n Q3 2025\n \n \n \n \n \n \n \n \n \n Q3 2024\n \n \n \n \n \n \n \n \n \n Q3 2025\n \n \n \n \n \n \n \n \n \n Q3 2024\n \n \n \n \n \n \n \n Revenue\n \n \n \n \n \n $ 1,084\n \n \n \n \n \n \n \n \n $ 1,080\n \n \n \n \n \n \n \n \n $ 1,084\n \n \n \n \n \n \n \n \n $ 1,080\n \n \n \n \n \n \n Gross margin\n \n \n \n \n \n 67.6 %\n \n \n \n \n \n \n \n \n 68.9 %\n \n \n \n \n \n \n \n \n 69.2 %\n \n \n \n \n \n \n \n \n 70.5 %\n \n \n \n \n \n \n Research and development (R&D) expense\n \n \n \n \n \n $ 229\n \n \n \n \n \n \n \n \n $ 253\n \n \n \n \n \n \n \n \n $ 228\n \n \n \n \n \n \n \n \n $ 249\n \n \n \n \n \n \n Selling, gene...